Literature DB >> 16611213

Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction.

Maxwell D Cummings1, Carsten Schubert, Daniel J Parks, Raul R Calvo, Louis V LaFrance, Jennifer Lattanze, Karen L Milkiewicz, Tianbao Lu.   

Abstract

Small molecule antagonists of protein-protein interactions represent a particular challenge for pharmaceutical discovery. One approach to finding molecules that can disrupt these interactions is to seek mimics of common protein structure motifs. We present an analysis of how molecules based on the 1,4-benzodiazepine-2,5-dione scaffold serve to mimic the side-chains presented by the hydrophobic face of two turns of an alpha-helix derived from the tumor suppressor protein p53, and thus antagonize the HDM2-p53 protein-protein binding interaction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611213     DOI: 10.1111/j.1747-0285.2006.00365.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  11 in total

1.  Multicomponent synthesis of dihydrobenzoxazepinones, bearing four diversity points, as potential α-helix mimics.

Authors:  Luca Banfi; Andrea Basso; Valentina Cerulli; Giuseppe Guanti; Paulina Lecinska; Ilaria Monfardini; Renata Riva
Journal:  Mol Divers       Date:  2009-11-28       Impact factor: 2.943

2.  Ligand binding mode prediction by docking: mdm2/mdmx inhibitors as a case study.

Authors:  Nagakumar Bharatham; Kavitha Bharatham; Anang A Shelat; Donald Bashford
Journal:  J Chem Inf Model       Date:  2014-01-21       Impact factor: 4.956

Review 3.  Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines.

Authors:  Barbara Gerratana
Journal:  Med Res Rev       Date:  2010-06-13       Impact factor: 12.944

4.  1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity.

Authors:  Yijun Huang; Siglinde Wolf; Michal Bista; Lidio Meireles; Carlos Camacho; Tad A Holak; Alexander Dömling
Journal:  Chem Biol Drug Des       Date:  2010-05-18       Impact factor: 2.817

Review 5.  P53 mdm2 inhibitors.

Authors:  Kareem Khoury; Alex Dömling
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 6.  Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes.

Authors:  Marta Pelay-Gimeno; Adrian Glas; Oliver Koch; Tom N Grossmann
Journal:  Angew Chem Int Ed Engl       Date:  2015-06-26       Impact factor: 15.336

7.  Docking Analysis and Multidimensional Hybrid QSAR Model of 1,4-Benzodiazepine-2,5-Diones as HDM2 Antagonists.

Authors:  Yujie Dai; Nan Chen; Qiang Wang; Heng Zheng; Xiuli Zhang; Shiru Jia; Lilong Dong; Dacheng Feng
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

8.  Structure-based virtual screening and characterization of a novel IL-6 antagonistic compound from synthetic compound database.

Authors:  Jing Wang; Chunxia Qiao; He Xiao; Zhou Lin; Yan Li; Jiyan Zhang; Beifen Shen; Tinghuan Fu; Jiannan Feng
Journal:  Drug Des Devel Ther       Date:  2016-12-15       Impact factor: 4.162

Review 9.  Multi-Facial, Non-Peptidic α-Helix Mimetics.

Authors:  Maryanna E Lanning; Steven Fletcher
Journal:  Biology (Basel)       Date:  2015-08-31

Review 10.  Chemical Variations on the p53 Reactivation Theme.

Authors:  Carlos J A Ribeiro; Cecília M P Rodrigues; Rui Moreira; Maria M M Santos
Journal:  Pharmaceuticals (Basel)       Date:  2016-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.